VIEWS: 1 PAGES: 1 CATEGORY: Business & Economics POSTED ON: 6/11/2010
The incoming FDA commissioner faces something akin to the theme of the old Mission Impossible television series as the agency admits to yet another management gaffe in its bizarre "disinvitation," at Eli Lilly's request, of a dissident voice on an advisory committee days before it was to vote on the company's new drug, prasugrel. Absent that voice, belonging to Sanjay Kaul, a Cedars-Sinai Heart Institute cardiologist, the panel voted 9-0 in favor of prasugrel's approval.
As We See It James G Dickinson Medical Marketing and Media; Apr 2009; 44, 4; Docstoc pg. 32 Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Pages to are hidden for
"As We See It"Please download to view full document